Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis

Hepatic encephalopathy (HE) is a devastating complication of cirrhosis. Data are limited regarding the incidence of and risk factors for HE among contemporary patients in the context of the shifting epidemiology of cirrhosis. We examined a 20% random sample of U.S. Medicare enrollees with cirrhosis...

Full description

Bibliographic Details
Main Authors: Elliot B. Tapper, James B. Henderson, Neehar D. Parikh, George N. Ioannou, Anna S. Lok
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1425
id doaj-479c4fff57ab4c9ca932e8a808f9d12c
record_format Article
spelling doaj-479c4fff57ab4c9ca932e8a808f9d12c2020-11-25T01:01:09ZengWileyHepatology Communications2471-254X2019-11-013111510151910.1002/hep4.1425Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With CirrhosisElliot B. Tapper0James B. Henderson1Neehar D. Parikh2George N. Ioannou3Anna S. Lok4Division of Gastroenterology and Hepatology University of Michigan Ann Arbor MICenter for Statistical Consultation and Research University of Michigan Ann Arbor MIDivision of Gastroenterology and Hepatology University of Michigan Ann Arbor MIDivision of Gastroenterology Department of Medicine Veterans Affairs Puget Sound Healthcare System and University of Washington Seattle WADivision of Gastroenterology and Hepatology University of Michigan Ann Arbor MIHepatic encephalopathy (HE) is a devastating complication of cirrhosis. Data are limited regarding the incidence of and risk factors for HE among contemporary patients in the context of the shifting epidemiology of cirrhosis. We examined a 20% random sample of U.S. Medicare enrollees with cirrhosis and Part D prescription coverage from 2008 to 2014. We modelled incident HE using demographic, clinical, and pharmacologic data. Risk factors for HE were evaluated, including demographics/socioeconomics, cirrhosis etiology, severity of liver disease, and pharmacotherapy, along with gastroenterology consultation, as time‐varying covariates. Among 166,192 Medicare enrollees with cirrhosis followed for 5.25 (interquartile range [IQR], 2.00‐7.00) years, the overall incidence of HE was 11.6 per 100 patient‐years. The cohort's median age was 65 years (IQR, 57‐72), 31% had alcohol‐related cirrhosis, and 49% had likely nonalcoholic fatty liver disease cirrhosis. The two strongest associations with HE were alcohol‐related cirrhosis (adjusted hazard ratio [AHR], 1.44; 95% confidence interval [CI], 1.40, 1.47, relative to nonalcoholic nonviral cirrhosis) and the presence of portal hypertension (AHR, 3.42; 95% CI, 3.34, 3.50). Adjusting for confounders, benzodiazepines (AHR, 1.24; 95% CI, 1.21, 1.27), gamma aminobutyric acid (GABA)ergics (AHR, 1.17; 95% CI, 1.14, 1.21), opioids (AHR, 1.24; 95% CI, 1.21, 1.27), and proton pump inhibitors (PPIs) (AHR, 1.41; 95% CI, 1.38, 1.45) were all associated with incident HE. Only benzodiazepines, however, were associated with the risk of hospitalization with HE (incidence‐rate ratio, 1.23; 95% CI, 1.20, 1.26). Conclusion: Novel data regarding the risk of HE for contemporary patients with cirrhosis are provided. The incidence of HE in an older population of Americans with cirrhosis is high, particularly among those with alcohol‐related cirrhosis and portal hypertension. Several medication classes, namely PPIs, opiates, GABAergics, and benzodiazepines, represent potentially modifiable risk factors for HE.https://doi.org/10.1002/hep4.1425
collection DOAJ
language English
format Article
sources DOAJ
author Elliot B. Tapper
James B. Henderson
Neehar D. Parikh
George N. Ioannou
Anna S. Lok
spellingShingle Elliot B. Tapper
James B. Henderson
Neehar D. Parikh
George N. Ioannou
Anna S. Lok
Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis
Hepatology Communications
author_facet Elliot B. Tapper
James B. Henderson
Neehar D. Parikh
George N. Ioannou
Anna S. Lok
author_sort Elliot B. Tapper
title Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis
title_short Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis
title_full Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis
title_fullStr Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis
title_full_unstemmed Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis
title_sort incidence of and risk factors for hepatic encephalopathy in a population‐based cohort of americans with cirrhosis
publisher Wiley
series Hepatology Communications
issn 2471-254X
publishDate 2019-11-01
description Hepatic encephalopathy (HE) is a devastating complication of cirrhosis. Data are limited regarding the incidence of and risk factors for HE among contemporary patients in the context of the shifting epidemiology of cirrhosis. We examined a 20% random sample of U.S. Medicare enrollees with cirrhosis and Part D prescription coverage from 2008 to 2014. We modelled incident HE using demographic, clinical, and pharmacologic data. Risk factors for HE were evaluated, including demographics/socioeconomics, cirrhosis etiology, severity of liver disease, and pharmacotherapy, along with gastroenterology consultation, as time‐varying covariates. Among 166,192 Medicare enrollees with cirrhosis followed for 5.25 (interquartile range [IQR], 2.00‐7.00) years, the overall incidence of HE was 11.6 per 100 patient‐years. The cohort's median age was 65 years (IQR, 57‐72), 31% had alcohol‐related cirrhosis, and 49% had likely nonalcoholic fatty liver disease cirrhosis. The two strongest associations with HE were alcohol‐related cirrhosis (adjusted hazard ratio [AHR], 1.44; 95% confidence interval [CI], 1.40, 1.47, relative to nonalcoholic nonviral cirrhosis) and the presence of portal hypertension (AHR, 3.42; 95% CI, 3.34, 3.50). Adjusting for confounders, benzodiazepines (AHR, 1.24; 95% CI, 1.21, 1.27), gamma aminobutyric acid (GABA)ergics (AHR, 1.17; 95% CI, 1.14, 1.21), opioids (AHR, 1.24; 95% CI, 1.21, 1.27), and proton pump inhibitors (PPIs) (AHR, 1.41; 95% CI, 1.38, 1.45) were all associated with incident HE. Only benzodiazepines, however, were associated with the risk of hospitalization with HE (incidence‐rate ratio, 1.23; 95% CI, 1.20, 1.26). Conclusion: Novel data regarding the risk of HE for contemporary patients with cirrhosis are provided. The incidence of HE in an older population of Americans with cirrhosis is high, particularly among those with alcohol‐related cirrhosis and portal hypertension. Several medication classes, namely PPIs, opiates, GABAergics, and benzodiazepines, represent potentially modifiable risk factors for HE.
url https://doi.org/10.1002/hep4.1425
work_keys_str_mv AT elliotbtapper incidenceofandriskfactorsforhepaticencephalopathyinapopulationbasedcohortofamericanswithcirrhosis
AT jamesbhenderson incidenceofandriskfactorsforhepaticencephalopathyinapopulationbasedcohortofamericanswithcirrhosis
AT neehardparikh incidenceofandriskfactorsforhepaticencephalopathyinapopulationbasedcohortofamericanswithcirrhosis
AT georgenioannou incidenceofandriskfactorsforhepaticencephalopathyinapopulationbasedcohortofamericanswithcirrhosis
AT annaslok incidenceofandriskfactorsforhepaticencephalopathyinapopulationbasedcohortofamericanswithcirrhosis
_version_ 1725210472894955520